Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies
Pfizer
Pfizer
Autolus Limited
MedImmune LLC
NeoImmuneTech
MedImmune LLC
Eli Lilly and Company
Aragon Pharmaceuticals, Inc.
Bristol-Myers Squibb
BeOne Medicines
Acerta Pharma BV
Transgene
Incyte Corporation
Sanofi
AstraZeneca
Enterome
AstraZeneca
Teva Branded Pharmaceutical Products R&D, Inc.
AstraZeneca
Dizal Pharmaceuticals
Teva Branded Pharmaceutical Products R&D, Inc.
Cytovation AS
Takeda
Bristol-Myers Squibb
Incyte Corporation
Hope Biosciences Research Foundation
Exelixis
Aileron Therapeutics, Inc.
Pfizer
Bristol-Myers Squibb
Eli Lilly and Company
Astellas Pharma Inc
Bristol-Myers Squibb
AstraZeneca
Bristol-Myers Squibb
Seagen Inc.
Acerta Pharma BV
Takeda
Eli Lilly and Company
Bristol-Myers Squibb
Cytovation AS
NantCell, Inc.
Sanofi
Hoffmann-La Roche
Sotio Biotech Inc.
Pfizer
Takeda
Hoffmann-La Roche
Alaunos Therapeutics
Barinthus Biotherapeutics
Incyte Corporation